There have been many articles highlighting differences and similarities between complex regional pain syndrome (CRPS) and functional neurological disorders (FND) but until now the discussions have ...
Associate Professor D R Royall, Department of Psychiatry, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78284–7792, USA. Telephone 001 210 567 ...
Peripheral neuropathies are classified as primarily demyelinating or axonal. Microstructural alterations of the nodal region are the key to understand the pathophysiology of neuropathies with ...
a Department of Neurosurgery, Benjamin Franklin Medical Center, Free University of Berlin, Hindenburgdamm 30, 12200 Berlin, Germany, b Department of Radiology Dr Ruediger Stendel, Department of ...
1 Dementia Research Group, Institute of Neurology, University College, London, UK 2 Dementia Research Group, Institute of Neurology, University College, London; and Division of Neuroscience and ...
aDepartment of Neurology, Ward 11, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK, bDepartment of Human Genetics, cDepartment of Neurology, Manchester Royal Infirmary, Manchester UK If you ...
School of Medicine, University of California, San Francisco, CA, USA Dr MJ Aminoff, Box 0114, Room M-794, University of California, San Francisco, CA 94143, USA. Telephone 001 415 476 1986. If you ...
1 Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne, UK 2 Department of Neurophysiology, Royal Victoria Infirmary, Newcastle upon Tyne, UK 3 Department of Rheumatology, Royal ...
Objective To examine 36-month effects of bilateral subthalamic nucleus deep brain stimulation (STN-DBS) on non-motor symptoms (NMS) compared with standard-of-care medical treatment (MED) in ...
a Department of Medicine (Neurology), University of Wales College of Medicine, Cardiff, UK, b The Common Cold Centre, Cardiff School of Biosciences, Cardiff University, UK Dr S Hadjikoutis, Department ...
From 1979-85, 2435 patients with a transient ischaemic attack or minor ischaemic stroke were randomly allocated to receive long term "blind" treatment with aspirin 600 mg twice daily (n = 815), ...
Subcutaneous ocrelizumab in multiple sclerosis: results of the phase Ib dose-finding OCARINA I study
Objectives OCARINA I (NCT03972306) is a Phase Ib, dose-finding study exploring a novel subcutaneous formulation for ocrelizumab relapsing and primary progressive multiple sclerosis (RMS/PPMS), every ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback